Elevidys Payer Gauntlet Complicated By Fear Patients Could Age Out Of DMD Gene Therapy’s Label

Launching much faster than it told a US FDA advisory committee that it would, Sarepta is focusing on Duchenne muscular dystrophy patients about to turn six in the initial roll-out of its gene therapy Elevidys amid fears the wait for payer authorization could mean losing access to the treatment.